• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Turk Thorac J . Evaluation of the Hospitalized Coronavirus Disease 2019 Patients in First 3 Months of the Pandemic

tetano

Editor, Senior Moderator
Turk Thorac J


. 2022 Jan;23(1):52-57.
doi: 10.5152/TurkThoracJ.2022.21118.
Evaluation of the Hospitalized Coronavirus Disease 2019 Patients in First 3 Months of the Pandemic


Sevil Alkan[SUP] 1 [/SUP], Anıl Akça[SUP] 1 [/SUP], Alper Şener[SUP] 1 [/SUP], Ebru Doğan[SUP] 1 [/SUP], Uğur Gönlügür[SUP] 2 [/SUP], Tuncer Şimşek[SUP] 3 [/SUP], Şule Özer[SUP] 4 [/SUP], Buse Yüksel[SUP] 5 [/SUP], Koray Öz[SUP] 4 [/SUP], Kemal Kurt[SUP] 6 [/SUP]



Affiliations

Abstract

Objective: Data about Turkish coronavirus disease 2019 patients are limited. We evaluated hospitalized coronavirus disease 2019 patients who were followed up in the first 3 months of the pandemic.
Material and methods: This retrospective, single-center, observational study included 415 confirmed hospitalized coronavirus disease 2019 patients. The patients were divided into groups, namely, mild, moderate, and critically ill patients. Symptoms at the time of admission, clinical, laboratory, and imaging findings were examined.
Results: In our study, 6.74% of coronavirus disease 2019 patients had severe disease, 59.5% were male, and the mortality rate was 11.3%. Diabetes mellitus and chronic obstructive pulmonary disease were more frequently seen in critically ill patient groups and hypertension in moderate patient groups. Anemia and aspartate aminotransferase levels were higher in non-survivors among mild coronavirus disease 2019 patients. In the moderate patients' group, aspartate aminotransferase, lactate dehydrogenase, international normalized ratio, ferritin, and D-dimer levels were higher and lymphocyte, hemoglobin levels were lower; in the critically ill patients' group, platelets were lower and uric acid levels were higher in non-survivor patients.
Conclusion: In mild patients, anemia, lymphopenia, and increased aspartate aminotransferase levels; in moderate patients, leukopenia, anemia, and increased aspartate aminotransferase, lactate dehydrogenase, international normalized ratio, ferritin, and D-dimer levels; in the critically ill patient group, lower platelet and increased uric acid levels should be followed closely as they are mortality predictors.
 
Back
Top Bottom